-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 9, 2022, CelerisTx announced a research collaboration agreement with Merck KGaA, Germany, to use CelerisTx's graph-based artificial intelligence (AI) technology platform to discover and design novel small molecule binders and bifunctional protein degradation agent
.
Protein degradation-targeted chimeras (PROTACs) technology and molecular glues are becoming one of the hot spots in the development of new drugs
.
CelerisTx was founded in 2020 to fill the knowledge gap for rationally designing these compounds
References:
[1] CelerisTx in research collaboration with Merck KGaA, Darmstadt, Germany on AI-enabled degrader discovery.
[2] Menlo Park, CA, February 9, 2022 - CelerisTx in Artificial Intelligence research collaboration with Merck KGaA, Darmstadt, Germany on AI-enabled.
[3] Merck KGaA enlists little AI player on protein degrader discovery.
(Original abridged)